Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancer

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: To define the impact of polymorphisms in genes involved in platinum-taxane and estrogen activity in the outcome of platinum-based treated ovarian cancer patients (OCP). Patients & Methods: Two hundred and thirty OCP were analyzed for 124 germ-line polymorphisms to generate a prognostic score for overall survival (OS), progression-free survival (PFS) and platinum-free interval (PFI). Results: ABCG2 rs3219191D>I, UGT1A rs10929302G>A and UGT1A rs2741045T>C polymorphisms were significantly associated with all three parameters (OS, PFS and PFI) and were used to generate a score. Patients in high-risk group had a poorer OS (hazard ratio [HR]: 1.8; 95% CI: 1.3-2.7; p = 0.0019), PFS (HR: 2.0; 95% CI: 1.4-2.9; p < 0.0001) and PFI (HR: 1.9; 95% CI: 1.4-2.8; p = 0.0002) compared with those in low-risk group. Conclusion: The prognostic-score including polymorphisms involved in drug and estrogen pathways stratifies OCP according to OS, PFS and PFI.

Original languageEnglish
Pages (from-to)995-1010
Number of pages16
JournalPharmacogenomics
Volume21
Issue number14
DOIs
Publication statusPublished - Sep 2020

Keywords

  • estrogen
  • ovarian cancer
  • pharmacogenetics
  • platinum therapy
  • polymorphism
  • survival

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Fingerprint Dive into the research topics of 'Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancer'. Together they form a unique fingerprint.

Cite this